Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: Accurately Predicting Nodal pCR Holds the Key to Axillary Surgery De-escalation Strategies

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455–61.

    Article  CAS  Google Scholar 

  2. Ollila DW, Cirrincione CT, Berry DA, et al. Axillary management of stage II/III breast cancer in patients treated with neoadjuvant systemic therapy: results of CALGB 40601 (HER2-positive) and CALGB 40603 (triple-negative). J Am Coll Surg. 2017;224:688–94.

    Article  Google Scholar 

  3. Weiss A, Campbell J, Ballman KV, et al. Factors associated with nodal pathologic complete response among breast cancer patients treated with neoadjuvant chemotherapy: results of CALGB 40601 (HER2+) and 40603 (triple-negative) (Alliance). Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-09897-w.

    Article  PubMed  Google Scholar 

  4. Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072–8.

    Article  CAS  Google Scholar 

  5. Tung N. (CompassHER2-pCR): preoperative THP and postoperative HP in patients who achieve a pathologic complete response. ClinicalTrials.gov Identifier: NCT04266249.

  6. O’Sullivan C. The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib. ClinicalTrials.gov Identifier: NCT04457596.

Download references

Author information

Authors and Affiliations

  1. Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, MA, USA

    Anna Weiss MD

  2. Breast Oncology Program, Brigham and Women’s Hospital, Dana-Farber/Brigham and Women’s Cancer Center, Boston, MA, USA

    Anna Weiss MD

  3. Department of Surgery, Division of Surgical Oncology, Yale Cancer Center, New Haven, CT, USA

    Mehra Golshan MD, MBA

  4. Department of Surgery, Division of Surgical Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA

    David W. Ollila MD

Authors
  1. Anna Weiss MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mehra Golshan MD, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David W. Ollila MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anna Weiss MD.

Ethics declarations

Disclosure

There are no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weiss, A., Golshan, M. & Ollila, D.W. ASO Author Reflections: Accurately Predicting Nodal pCR Holds the Key to Axillary Surgery De-escalation Strategies. Ann Surg Oncol 28, 5972–5973 (2021). https://doi.org/10.1245/s10434-021-09953-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-09953-5

Search

Navigation